Cargando…
Modified Lipid Nanocapsules for Targeted Tanshinone IIA Delivery in Liver Fibrosis
INTRODUCTION: Liver fibrosis represents a serious global disease with no approved treatment. Tanshinone IIA (TSIIA) is a phytomedicine with documented activity in treating many hepatic disorders. TSIIA has been reported to have potent anti-inflammatory and antioxidant properties. It can also induce...
Autores principales: | Ashour, Asmaa A, El-Kamel, Amal H, Abdelmonsif, Doaa A, Khalifa, Hoda M, Ramadan, Alyaa A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671377/ https://www.ncbi.nlm.nih.gov/pubmed/34916792 http://dx.doi.org/10.2147/IJN.S331690 |
Ejemplares similares
-
Tanshinone IIA loaded bioactive nanoemulsion for alleviation of lipopolysaccharide induced acute lung injury via inhibition of endothelial glycocalyx shedding
por: El-Moslemany, Riham M., et al.
Publicado: (2022) -
Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules
por: El-Sheridy, Nabila A., et al.
Publicado: (2021) -
Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis in rats
por: HE, HUANYU, et al.
Publicado: (2015) -
Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study
por: Chan, Szu-Erh, et al.
Publicado: (2011) -
Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA
por: Hu, Xixi, et al.
Publicado: (2021)